High-risk human papillomavirus cervical infection prevalence: a nationwide retrospective study comparing opportunistic and organised screening, France, 2020 to 2023.

ABSTRACT: BACKGROUNDIn France, cervical cancer screening for females aged 30--65 years primarily tests for high-risk (HR) human papillomavirus (HPV) infections.AIMWe aimed to map the prevalence of cervical infections caused by HPV16 and/or 18, or by any of 12 other carcinogenic HPV genotypes and compare prevalence estimates from tests from spontaneous medical visits (opportunistic screening) or the national screening programme (organised screening).METHODSWe extracted data from a large network of biology laboratories, containing all available results from HR HPV tests performed between 1 January 2020 and 30 November 2023 in metropolitan France. A full hierarchical Bayesian model was used to compute spatially resolved expected prevalence maps at the postcode level.RESULTSThe analytic sample contained

SUBMITTER: Supplisson O 

PROVIDER: S-EPMC12273260 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature